ARTICLE | Clinical News
Miravant continues SnET2 Phase III trials
January 22, 2001 8:00 AM UTC
MRVT said that based on an interim analysis, partner Pharmacia (PHA) will continue to their 24-month conclusion two Phase III trials of MRVT's SnET2 photodynamic therapy to treat the wet form of age-r...